FY2025 · ended Dec 31, 2025 · Revenue $726.41M, +7.6% YoY · Filed Feb 26, 2026
Viatris Inc. (PCRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $726.4 million and net income of $7.0 million. Free cash flow was $136.7 million. As of Jun 30, 2026 it held $251.0 million in cash and investments and $412.1 million in total debt.
Revenue (TTM)
$746.16M
Net income (TTM)
$14.64M
+111.5% vs year-ago TTM
Operating cash flow (TTM)
$187.66M
+39.5% vs year-ago TTM
Free cash flow (TTM)
$179.51M
+53.3% vs year-ago TTM
EPS (TTM)
$0.34
+111.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
40.49M
-12.5% vs prior year
Net cash
$-161.09M
as of Jun 30, 2026
Operating margin
2.7%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1396814
- Former names
- Pacira Pharmaceuticals, Inc. (until Apr 9, 2019); PACIRA INC (until Nov 5, 2008); Blue Acquisition Corp (until Apr 16, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $726.4M | — | $675.0M | $666.8M | $541.5M |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M |
| Diluted EPS | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 |
| Operating cash flow | $152.0M | $189.4M | $154.6M | $145.3M | $125.7M |
| Free cash flow | $136.7M | $178.8M | $139.5M | $115.2M | $79.9M |
| Total assets | $1.3B | $1.6B | $1.6B | $1.7B | $2.1B |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.3B |
| Stockholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M |
| Cash and investments | $238.4M | $484.6M | $281.0M | $325.9M | $656.4M |
| Total debt | $418.2M | $638.9M | $586.0M | $73.9M | $79.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 8, 2026 | Oct 8, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 30, 2026 | Jun 28, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Jun 11, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
All 1002 Viatris Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.